Market Overview

Cyclacel Reports Positive Phase 2 Data of Sapacitabine for MDS at ASH


Cyclacel Pharmaceuticals (Nasdaq: CYCC) (Nasdaq: CYCCP) today announced new, primary endpoint data from an ongoing, open-label, multicenter, randomized Phase 2 trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine and/or decitabine. The 7-day dose regimen of 200 mg twice daily (Arm G), appears to be a better schedule with a one-year survival rate of 38%, median overall survival of approximately 10 months and response rate of 19%. The 30-day mortality from all causes for all patients is 5%. Data were presented at a poster on December 8, 2013 during the 2013 American Society of Hematology (ASH) Meeting and Exposition held in New Orleans, LA.#ASH13

See full press release

Posted-In: News Guidance Management Global


Related Articles (CYCC + CYCCP)

View Comments and Join the Discussion!

Chelsea Therapeutics Announces First Patient Dosed in NORTHERA Study 401 for Treatment of Symptomatic nOH

China Zenix Auto Announces Special Committee of the Board of Directors to Consider Restructuring Proposal